Ascletis Inc. (CN)

https://www.ascletis.com

Ascletis is a leading biotechnology company dedicated to discovering, developing and commercializing new treatments for liver diseases. Ascletis has assembled an entrepreneurial management and senior scientific team with a track record of successful pharmaceutical discovery and development at major global pharmaceutical companies. To date the company has added four late-stage candidates to its product portfolio: Danoprevir (ASC08), an NDA-filed HCV protease inhibitor, licensed from Roche; Ravidasvir (ASC16), phase II completed HCV NS5A inhibitor, licensed from Presidio Pharmaceuticals; ASC06, a clinical stage, first-in-class, RNAi therapeutic for the treatment of liver cancers, licensed from Alnylam Pharmaceuticals; and ASC09, a phase IIa completed HIV protease inhibitor, licensed from Janssen, a Johnson & Johnson company. *

	Start	2013-04-15 existent
	Industry	anti-infective drug
	Industry 2	cancer drug

	Region	Hangzhou
	Country	China
	Street	1197 Binan Road Binjiang District
	City	n. a. Hangzhou
	Tel	+86-571-86593288
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Medivir AB. (8/18/17). "Press Release: Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis". Stockholm & Hangzhou.

		Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Ascletis Inc. (CN)

[1] Medivir AB. (8/18/17). "Press Release: Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis". Stockholm & Hangzhou....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]